Evolent Health, Inc. (NYSE:EVH) CEO Seth Blackley Acquires 55,225 Shares

Evolent Health, Inc. (NYSE:EVH) CEO Seth Blackley bought 55,225 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was bought at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the completion of the purchase, the chief executive officer now directly owns 762,217 shares of the company’s stock, valued at $6,867,575.17. This represents a 7.81 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Evolent Health Trading Up 1.0 %

NYSE EVH opened at $9.49 on Thursday. The stock has a market cap of $1.11 billion, a P/E ratio of -11.57 and a beta of 1.49. Evolent Health, Inc. has a fifty-two week low of $8.35 and a fifty-two week high of $34.07. The stock has a 50 day simple moving average of $10.26 and a two-hundred day simple moving average of $17.23. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). The business had revenue of $646.54 million during the quarter, compared to analysts’ expectations of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. On average, analysts forecast that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Truist Financial lowered their price objective on shares of Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. BTIG Research reduced their target price on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, December 3rd. UBS Group dropped their price target on Evolent Health from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, January 16th. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Evolent Health in a report on Friday, February 14th. Finally, Oppenheimer decreased their price objective on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $17.71.

Institutional Investors Weigh In On Evolent Health

A number of large investors have recently modified their holdings of EVH. Pilgrim Partners Asia Pte Ltd bought a new position in Evolent Health in the fourth quarter worth about $26,000. R Squared Ltd purchased a new position in shares of Evolent Health during the 4th quarter worth approximately $31,000. AlphaQuest LLC raised its position in shares of Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock worth $34,000 after acquiring an additional 3,031 shares in the last quarter. Covestor Ltd lifted its stake in shares of Evolent Health by 138.1% in the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after purchasing an additional 826 shares during the period. Finally, Parkside Financial Bank & Trust boosted its position in shares of Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock valued at $56,000 after purchasing an additional 2,358 shares in the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.